A Phase 2 efficacy study to evaluate VL-2397 in the treatment of patients with invasive aspergillosis.

Trial Profile

A Phase 2 efficacy study to evaluate VL-2397 in the treatment of patients with invasive aspergillosis.

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs VL 2397
  • Indications Aspergillosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Nov 2016 New trial record
    • 03 Nov 2016 According a Vical media release, company is working with FDA on design of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top